Pub Date : 2026-03-01Epub Date: 2025-06-12DOI: 10.1016/j.jaac.2025.06.002
Giorgia Picci PhD
{"title":"Editorial: Neuroprotection Across Generations: Maternal Childhood Trauma and the Developing Amygdala","authors":"Giorgia Picci PhD","doi":"10.1016/j.jaac.2025.06.002","DOIUrl":"10.1016/j.jaac.2025.06.002","url":null,"abstract":"","PeriodicalId":17186,"journal":{"name":"Journal of the American Academy of Child and Adolescent Psychiatry","volume":"65 3","pages":"Pages 349-351"},"PeriodicalIF":9.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144289865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-01Epub Date: 2025-08-20DOI: 10.1016/j.jaac.2025.08.008
Janet Charoensook MD
{"title":"Editorial: Neurodevelopmental Outcomes of Prenatal Antipsychotic Medication Exposure","authors":"Janet Charoensook MD","doi":"10.1016/j.jaac.2025.08.008","DOIUrl":"10.1016/j.jaac.2025.08.008","url":null,"abstract":"","PeriodicalId":17186,"journal":{"name":"Journal of the American Academy of Child and Adolescent Psychiatry","volume":"65 3","pages":"Pages 340-342"},"PeriodicalIF":9.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144898335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-01Epub Date: 2025-05-23DOI: 10.1016/j.jaac.2025.05.009
Magdalena Janecka PhD , Candice Medina MS , Nina Zaks MS , Khaoula Ben Messaoud PhD , Vahe Khachadourian MD, MPH, PhD , Lisa A. Croen PhD
{"title":"Unveiling Disparities: The Case for Group-Specific Analyses in Child Psychiatry","authors":"Magdalena Janecka PhD , Candice Medina MS , Nina Zaks MS , Khaoula Ben Messaoud PhD , Vahe Khachadourian MD, MPH, PhD , Lisa A. Croen PhD","doi":"10.1016/j.jaac.2025.05.009","DOIUrl":"10.1016/j.jaac.2025.05.009","url":null,"abstract":"","PeriodicalId":17186,"journal":{"name":"Journal of the American Academy of Child and Adolescent Psychiatry","volume":"65 3","pages":"Pages 337-339"},"PeriodicalIF":9.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144136660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-01Epub Date: 2025-06-18DOI: 10.1016/j.jaac.2025.06.008
Misty C. Richards MD, MS
{"title":"Editorial: Reframing Risk: Antidepressant Use in Pregnancy and Offspring Mental Health","authors":"Misty C. Richards MD, MS","doi":"10.1016/j.jaac.2025.06.008","DOIUrl":"10.1016/j.jaac.2025.06.008","url":null,"abstract":"","PeriodicalId":17186,"journal":{"name":"Journal of the American Academy of Child and Adolescent Psychiatry","volume":"65 3","pages":"Pages 346-348"},"PeriodicalIF":9.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144335317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-01Epub Date: 2025-08-28DOI: 10.1016/j.jaac.2025.08.018
Douglas Teixeira Leffa MD, PhD
{"title":"Editorial: Cautious Optimism for Noninvasive Brain Stimulation in Attention-Deficit/Hyperactivity Disorder: What Does the Evidence Show?","authors":"Douglas Teixeira Leffa MD, PhD","doi":"10.1016/j.jaac.2025.08.018","DOIUrl":"10.1016/j.jaac.2025.08.018","url":null,"abstract":"","PeriodicalId":17186,"journal":{"name":"Journal of the American Academy of Child and Adolescent Psychiatry","volume":"65 3","pages":"Pages 343-345"},"PeriodicalIF":9.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144958746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-01Epub Date: 2025-11-06DOI: 10.1016/j.jaac.2025.10.015
Dae Sun Hwang BA
{"title":"Hospital Playlist","authors":"Dae Sun Hwang BA","doi":"10.1016/j.jaac.2025.10.015","DOIUrl":"10.1016/j.jaac.2025.10.015","url":null,"abstract":"","PeriodicalId":17186,"journal":{"name":"Journal of the American Academy of Child and Adolescent Psychiatry","volume":"65 3","pages":"Pages 456-457"},"PeriodicalIF":9.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145447441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-01Epub Date: 2025-10-30DOI: 10.1016/j.jaac.2025.10.014
Tyler C. Kung BA , Anna Hong BSA
{"title":"Everything I Never Told You","authors":"Tyler C. Kung BA , Anna Hong BSA","doi":"10.1016/j.jaac.2025.10.014","DOIUrl":"10.1016/j.jaac.2025.10.014","url":null,"abstract":"","PeriodicalId":17186,"journal":{"name":"Journal of the American Academy of Child and Adolescent Psychiatry","volume":"65 3","pages":"Pages 457-458"},"PeriodicalIF":9.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145397128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-01Epub Date: 2025-04-07DOI: 10.1016/j.jaac.2025.03.026
Ardesheer Talati PhD , Jennifer L. Vande Voort MD , Launia J. White BS , David Hodge MS , Cynthia J. Stoppel BS , Myrna M. Weissman PhD , Jay A. Gingrich MD, PhD , William V. Bobo MD, MPH
Objective
To examine the associations of serotonergic antidepressant exposure during pregnancy with the risk of depression and anxiety disorders in offspring.
Method
The Mayo Clinic Rochester Epidemiology Project medical records-linkage system was used to study offspring born to mothers who were prescribed a selective serotonin reuptake inhibitor or serotonin-norepinephrine reuptake inhibitor (S/NRI users, n = 837) during pregnancy (1997-2010). Cox regression models were used to calculate hazard ratios to examine associations of S/NRIs with diagnosed depression and anxiety, defined based on a review of medical records by 2 board-certified psychiatrists, vs no maternal antidepressant use during pregnancy (nonusers, n = 863) and maternal antidepressant use in the year prior to pregnancy (former users, n = 399) as control groups.
Results
After all adjustments for covariates, children born to S/NRI users during pregnancy did not differ in onset of depression or anxiety from the children of nonusers (adjusted hazard ratio = 1.00, 95% CI [0.74, 1.85]) or former users (adjusted hazard ratio = 0.94, 95% CI [0.69, 1.27]). These associations were similar when exposure was limited only to selective serotonin reuptake inhibitors.
Conclusion
The results suggest that higher rates of childhood and adolescent depression or anxiety conditioned on maternal S/NRI use in pregnancy are more likely to be driven by maternal depression or underlying propensity for depression rather than direct pharmacological effects of in utero S/NRI exposure.
Plain language summary
The authors examined the association between exposure to serotonergic antidepressants during pregnancy and risk of having depression and anxiety in their offspring using data regarding 2,099 participants in the Mayo Clinic Rochester Epidemiology Project. After accounting for maternal depression, prenatal serotonergic antidepressant exposure was not associated with higher risk for these outcomes compared to either unexposed children or those whose mothers used antidepressants prior to but not during pregnancy. Findings suggest that increased depression and anxiety observed in prenatally exposed children is more likely to be driven by maternal depression or underlying factors rather than the direct effects of pharmacological exposure to serotonin-based antidepressant medication.
{"title":"Prenatal Antidepressant Exposure and Risk of Depression and Anxiety Disorders: An Electronic Health Records–Based Cohort Study","authors":"Ardesheer Talati PhD , Jennifer L. Vande Voort MD , Launia J. White BS , David Hodge MS , Cynthia J. Stoppel BS , Myrna M. Weissman PhD , Jay A. Gingrich MD, PhD , William V. Bobo MD, MPH","doi":"10.1016/j.jaac.2025.03.026","DOIUrl":"10.1016/j.jaac.2025.03.026","url":null,"abstract":"<div><h3>Objective</h3><div>To examine the associations of serotonergic antidepressant exposure during pregnancy with the risk of depression and anxiety disorders in offspring.</div></div><div><h3>Method</h3><div><span><span>The Mayo Clinic Rochester Epidemiology Project medical records-linkage system was used to study offspring born to mothers who were prescribed a </span>selective serotonin reuptake inhibitor<span> or serotonin-norepinephrine reuptake inhibitor (S/NRI users, n = 837) during pregnancy (1997-2010). Cox regression models were used to calculate hazard ratios to examine associations of S/NRIs with diagnosed depression and anxiety, defined based on a review of </span></span>medical records by 2 board-certified psychiatrists, vs no maternal antidepressant use during pregnancy (nonusers, n = 863) and maternal antidepressant use in the year prior to pregnancy (former users, n = 399) as control groups.</div></div><div><h3>Results</h3><div>After all adjustments for covariates, children born to S/NRI users during pregnancy did not differ in onset of depression or anxiety from the children of nonusers (adjusted hazard ratio = 1.00, 95% CI [0.74, 1.85]) or former users (adjusted hazard ratio = 0.94, 95% CI [0.69, 1.27]). These associations were similar when exposure was limited only to selective serotonin reuptake inhibitors.</div></div><div><h3>Conclusion</h3><div>The results suggest that higher rates of childhood and adolescent depression or anxiety conditioned on maternal S/NRI use in pregnancy are more likely to be driven by maternal depression or underlying propensity for depression rather than direct pharmacological effects of in utero S/NRI exposure.</div></div><div><h3>Plain language summary</h3><div>The authors examined the association between exposure to serotonergic antidepressants during pregnancy and risk of having depression and anxiety in their offspring using data regarding 2,099 participants in the Mayo Clinic Rochester Epidemiology Project. After accounting for maternal depression, prenatal serotonergic antidepressant exposure was not associated with higher risk for these outcomes compared to either unexposed children or those whose mothers used antidepressants prior to but not during pregnancy. Findings suggest that increased depression and anxiety observed in prenatally exposed children is more likely to be driven by maternal depression or underlying factors rather than the direct effects of pharmacological exposure to serotonin-based antidepressant medication.</div></div>","PeriodicalId":17186,"journal":{"name":"Journal of the American Academy of Child and Adolescent Psychiatry","volume":"65 3","pages":"Pages 408-419"},"PeriodicalIF":9.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143819290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-01Epub Date: 2025-04-23DOI: 10.1016/j.jaac.2025.04.008
Carly A. Kaplan BS , Eline M.P. Poels MD, PhD , Marion I. van den Heuvel PhD , Hilmar H. Bijma MD, PhD , Veerle Bergink MD, PhD , Anna-Sophie Rommel PhD , Thalia Robakis MD, PhD
<div><h3>Objective</h3><div>Antipsychotic medications are widely prescribed, including during pregnancy, and pregnant individuals worry about the potential sequelae for the child. Although antipsychotics do not seem to be teratogenic, the long-term neurodevelopmental impact of prenatal exposure remains unclear. A systematic review was conducted to determine if intrauterine antipsychotic exposure increases the risk of adverse neurodevelopmental outcomes.</div></div><div><h3>Method</h3><div>A systematic search was performed in MEDLINE, Cochrane, Embase, and PsycINFO for studies published before September 7, 2024. We included original studies assessing cognitive, motor, behavioral, social, and psychiatric outcomes in children prenatally exposed to antipsychotics, excluding case reports, reviews, preclinical studies, and studies without a control group. Quality and risk of bias were assessed using the Newcastle-Ottawa Scale.</div></div><div><h3>Results</h3><div>Of 1,349 studies identified, full text of 56 was screened, and 16 were included in the review. The number of exposed participants ranged from 11 to >15,000. In the 8 studies assessing motor development, early motor delays were observed but did not persist into later childhood. Neurodevelopmental disorders were assessed in 7 studies. Crude estimates showed greater risk in exposed children, but after adjusting for confounders, most studies found no significant risk. The mean NOS score was 7.1.</div></div><div><h3>Conclusion</h3><div>Transient motor delays may be associated with antipsychotic use during pregnancy, although future studies adjusting for confounding factors should clarify this risk. After adjustment for confounders, the risk of neurodevelopmental disorders in school-age children does not seem to be increased. Studies with longer follow-up time are required to further investigate the risk of neurodevelopmental disorders.</div></div><div><h3>Plain language summary</h3><div>This systematic review of research examines the mental, behavioral, and cognitive health outcomes of children whose mothers took antipsychotics during pregnancy. Sixteen articles were included in the review; the number of exposed participants in each study ranged from 11 to >15,000. The authors found that the majority of studies, especially those with longer-term follow-up and larger samples, did not identify increased neurodevelopmental problems in children who were exposed to antipsychotics during pregnancy. Some studies noted transient motor delays in exposed infants, but the authors found that they did not sufficiently account for the potential influence of severe maternal mental illness on this association.</div></div><div><h3>Clinical guidance</h3><div>• Antipsychotic use during pregnancy may be indicated for effective treatment of severe mental illness in pregnant women.</div><div>• A discussion that involves the risks of untreated maternal mental illness alongside existing data on antipsychotic exposur
{"title":"Systematic Review: Antipsychotic Medication in Pregnancy and Neurodevelopmental Outcomes in Children","authors":"Carly A. Kaplan BS , Eline M.P. Poels MD, PhD , Marion I. van den Heuvel PhD , Hilmar H. Bijma MD, PhD , Veerle Bergink MD, PhD , Anna-Sophie Rommel PhD , Thalia Robakis MD, PhD","doi":"10.1016/j.jaac.2025.04.008","DOIUrl":"10.1016/j.jaac.2025.04.008","url":null,"abstract":"<div><h3>Objective</h3><div>Antipsychotic medications are widely prescribed, including during pregnancy, and pregnant individuals worry about the potential sequelae for the child. Although antipsychotics do not seem to be teratogenic, the long-term neurodevelopmental impact of prenatal exposure remains unclear. A systematic review was conducted to determine if intrauterine antipsychotic exposure increases the risk of adverse neurodevelopmental outcomes.</div></div><div><h3>Method</h3><div>A systematic search was performed in MEDLINE, Cochrane, Embase, and PsycINFO for studies published before September 7, 2024. We included original studies assessing cognitive, motor, behavioral, social, and psychiatric outcomes in children prenatally exposed to antipsychotics, excluding case reports, reviews, preclinical studies, and studies without a control group. Quality and risk of bias were assessed using the Newcastle-Ottawa Scale.</div></div><div><h3>Results</h3><div>Of 1,349 studies identified, full text of 56 was screened, and 16 were included in the review. The number of exposed participants ranged from 11 to >15,000. In the 8 studies assessing motor development, early motor delays were observed but did not persist into later childhood. Neurodevelopmental disorders were assessed in 7 studies. Crude estimates showed greater risk in exposed children, but after adjusting for confounders, most studies found no significant risk. The mean NOS score was 7.1.</div></div><div><h3>Conclusion</h3><div>Transient motor delays may be associated with antipsychotic use during pregnancy, although future studies adjusting for confounding factors should clarify this risk. After adjustment for confounders, the risk of neurodevelopmental disorders in school-age children does not seem to be increased. Studies with longer follow-up time are required to further investigate the risk of neurodevelopmental disorders.</div></div><div><h3>Plain language summary</h3><div>This systematic review of research examines the mental, behavioral, and cognitive health outcomes of children whose mothers took antipsychotics during pregnancy. Sixteen articles were included in the review; the number of exposed participants in each study ranged from 11 to >15,000. The authors found that the majority of studies, especially those with longer-term follow-up and larger samples, did not identify increased neurodevelopmental problems in children who were exposed to antipsychotics during pregnancy. Some studies noted transient motor delays in exposed infants, but the authors found that they did not sufficiently account for the potential influence of severe maternal mental illness on this association.</div></div><div><h3>Clinical guidance</h3><div>• Antipsychotic use during pregnancy may be indicated for effective treatment of severe mental illness in pregnant women.</div><div>• A discussion that involves the risks of untreated maternal mental illness alongside existing data on antipsychotic exposur","PeriodicalId":17186,"journal":{"name":"Journal of the American Academy of Child and Adolescent Psychiatry","volume":"65 3","pages":"Pages 354-368"},"PeriodicalIF":9.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143876431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-01Epub Date: 2025-08-14DOI: 10.1016/j.jaac.2025.08.003
Zhenzhuang Zou MD , Jiaying Liu MD , Li Fu MD , Bo Huang MD , Shaohua Wang MD
{"title":"Reevaluating Suicide Risk Screening in Preadolescents: Beyond Safety Toward Strategic Integration","authors":"Zhenzhuang Zou MD , Jiaying Liu MD , Li Fu MD , Bo Huang MD , Shaohua Wang MD","doi":"10.1016/j.jaac.2025.08.003","DOIUrl":"10.1016/j.jaac.2025.08.003","url":null,"abstract":"","PeriodicalId":17186,"journal":{"name":"Journal of the American Academy of Child and Adolescent Psychiatry","volume":"65 3","pages":"Pages 327-328"},"PeriodicalIF":9.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144860123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}